Pixantrone lands orphan drug status in Europe

Submitted by Ross Bonander Wed 12/30/2009

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

The European Medicines Agency has granted orphan drug status to Cell Therapeutics' pixantrone for the treatment of diffuse large B-cell lymphoma (DLBCL), allowing the company to move ahead with a Marketing Authorization Application (MAA) by the middle of the year.

In the US, Cell Therapeutics has submitted a New Drug Application (NDA) to the FDA for pixantrone to treat relapsed/refractory aggressive Non-Hodgkin's lymphoma (NHL), which will be reviewed by the FDA's Oncologic Drugs Advisory Committee (ODAC) in February 2010. Currently fast-tracked, pixantrone's FDA status will be determined in late April 2010.

By Ross Bonander

- Source: Cell Therapeutics.
- Read about Phase II and Phase III clinical studies of pixantrone here.

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.